Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial
Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects o...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Guilan University of Medical Sciences
2017-09-01
|
Series: | Iranian Journal of Neurosurgery |
Subjects: | |
Online Access: | http://irjns.org/browse.php?a_code=A-10-181-1&slc_lang=en&sid=1 |
id |
doaj-728224ab00ac4429b209ed8c274e10eb |
---|---|
record_format |
Article |
spelling |
doaj-728224ab00ac4429b209ed8c274e10eb2021-04-02T19:16:28ZengGuilan University of Medical SciencesIranian Journal of Neurosurgery2423-64972423-68292017-09-01325157Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical TrialLeila Zareian0Amir Azarhomayoun1Maysam Alimohamadi2Mohammadreza Khajavi3Soodeh Razeghi-Jahromi4 MSc, Animal Physiology Department, Basic Sciences Faculty, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran MD, Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran MD, Brain and Spinal Cord Injury Research Center (BASIR), Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran MD, Department of Anesthesiology, Sina hospital, Tehran University of Medical Sciences, Tehran, Iran PhD, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects of epigallocatechin-3-gallate on the early clinical outcome and serum S100B levels (biomarker for brain tissue damage severity) in patients with moderate to severe traumatic brain injury. Methods and Materials/Patients: Thirty patients with moderate to severe traumatic brain injury admitted to the intensive care unit were enrolled. The patients were randomly allocated to treatment with either a daily oral dose of 400 mg epigallocatechin-3-gallate or placebo (distilled water) for seven days. The main outcome measures were duration of mechanical ventilation and ICU stay, Glasgow Coma Scale, and S100B protein level. Results: The results revealed a significant improvement in consciousness level after seven days in the epigallocatechin-3-gallate group (2.93±3.9 unit improvement in GCS versus 0.14±3.05 reduction in GCS, p-value:0.033). There was also a significantly shorter duration of mechanical ventilation in the epigallocatechin-3-gallate compared to the control group (5.1 days versus 9.8 days, p-value:0.02). Reduction of the serum S100B level was slightly higher in the epigallocatechin-3-gallate group (23.96 versus 18.6 pg/ml) but the difference was not statistically significant. Conclusion: Epigallocatechin-3-gallate supplementation had beneficial effects on consciousness level of the patients with moderate to severe traumatic brain injury in the acute phase.http://irjns.org/browse.php?a_code=A-10-181-1&slc_lang=en&sid=1Epigallocatechin-3-gallateHead TraumaNeuroprotectionS100B ProteinTraumatic Brain Injury |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Leila Zareian Amir Azarhomayoun Maysam Alimohamadi Mohammadreza Khajavi Soodeh Razeghi-Jahromi |
spellingShingle |
Leila Zareian Amir Azarhomayoun Maysam Alimohamadi Mohammadreza Khajavi Soodeh Razeghi-Jahromi Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial Iranian Journal of Neurosurgery Epigallocatechin-3-gallate Head Trauma Neuroprotection S100B Protein Traumatic Brain Injury |
author_facet |
Leila Zareian Amir Azarhomayoun Maysam Alimohamadi Mohammadreza Khajavi Soodeh Razeghi-Jahromi |
author_sort |
Leila Zareian |
title |
Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial |
title_short |
Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial |
title_full |
Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial |
title_fullStr |
Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial |
title_full_unstemmed |
Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial |
title_sort |
impact of acute phase epigallocatechin-3-gallate supplementation on consciousness and s100b serum levels in tbi patients: a double blind randomized clinical trial |
publisher |
Guilan University of Medical Sciences |
series |
Iranian Journal of Neurosurgery |
issn |
2423-6497 2423-6829 |
publishDate |
2017-09-01 |
description |
Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects of epigallocatechin-3-gallate on the early clinical outcome and serum S100B levels (biomarker for brain tissue damage severity) in patients with moderate to severe traumatic brain injury.
Methods and Materials/Patients: Thirty patients with moderate to severe traumatic brain injury admitted to the intensive care unit were enrolled. The patients were randomly allocated to treatment with either a daily oral dose of 400 mg epigallocatechin-3-gallate or placebo (distilled water) for seven days. The main outcome measures were duration of mechanical ventilation and ICU stay, Glasgow Coma Scale, and S100B protein level.
Results: The results revealed a significant improvement in consciousness level after seven days in the epigallocatechin-3-gallate group (2.93±3.9 unit improvement in GCS versus 0.14±3.05 reduction in GCS, p-value:0.033). There was also a significantly shorter duration of mechanical ventilation in the epigallocatechin-3-gallate compared to the control group (5.1 days versus 9.8 days, p-value:0.02). Reduction of the serum S100B level was slightly higher in the epigallocatechin-3-gallate group (23.96 versus 18.6 pg/ml) but the difference was not statistically significant.
Conclusion: Epigallocatechin-3-gallate supplementation had beneficial effects on consciousness level of the patients with moderate to severe traumatic brain injury in the acute phase. |
topic |
Epigallocatechin-3-gallate Head Trauma Neuroprotection S100B Protein Traumatic Brain Injury |
url |
http://irjns.org/browse.php?a_code=A-10-181-1&slc_lang=en&sid=1 |
work_keys_str_mv |
AT leilazareian impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial AT amirazarhomayoun impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial AT maysamalimohamadi impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial AT mohammadrezakhajavi impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial AT soodehrazeghijahromi impactofacutephaseepigallocatechin3gallatesupplementationonconsciousnessands100bserumlevelsintbipatientsadoubleblindrandomizedclinicaltrial |
_version_ |
1721549278604689408 |